This study examines the effectiveness of methylene blue (MB) in managing vasoplegic syndrome (VS) following cardiac surgery with cardiopulmonary bypass. A retrospective cohort of 2753 patients identified 200 with VS, of whom 84 received MB. Results showed MB shortened ICU stays, reduced norepinephrine requirements, and improved serum lactate levels, but did not significantly impact in-hospital mortality. The study suggests MB may aid recovery but calls for further research on its broader effectiveness.